Key Developments: Bacterin International Holdings Inc (BONE.A)
0.73USD
20 May 2013
$-0.02 (-2.67%)
$0.75
$0.73
$0.75
$0.72
3,300
16,949
$1.99
$0.51
Latest Key Developments (Source: Significant Developments)
Bacterin International Holdings Inc Announces Board Chnages-Form 8-K
Bacterin International Holdings Inc reported in its Form 8-K that Guy Cook resigned from his roles of Chief Executive Officer (CEO), President and Chairman of the Board effective April 5, 2013. The Board unanimously voted to have Kent Swanson, an existing independent director, serve as Acting Chairman of the Board. Current Chief Financial Officer, John Gandolfo, and Chief Operating Officer, Darrel Holmes, will jointly serve as interim Co-Chief Executive Officers until the Board appoints a new Chief Executive Officer. Full Article
Bacterin International Holdings Announces Transition of Executive Leadership
Bacterin International Holdings Inc announced that it will begin the process of identifying a successor to the Company’s Chief Executive Officer and President, Guy Cook. Mr. Cook will remain Chief Executive Officer and President until a successor is named. Thereafter, Mr. Cook will continue to work with the Company as a consultant and will continue to serve as Chairman of the Board. Full Article
Bacterin International Holdings Inc Comments On FY 2013 Earnings Guidance-Conference Call
Bacterin International Holdings Inc announced that it is successful in achieving the previously given 2013 revenue guidance of $38 to $40 million, as well as the expense reductions, the Company believe that it would generate positive operating income (EBIT) as well as positive EBITDA for fiscal 2013. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report EBIT of ($50) million and EBITDA of $0.31 million for fiscal 2013. Full Article
Bacterin International Holdings Inc Issues FY 2013 Revenue Guidance Above Analysts' Estimates-Conference Call
Bacterin International Holdings Inc announced that for fiscal 2013, it expect revenues to be between $38 and $40 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $35 million for fiscal 2013. Full Article
Bacterin International Holdings Inc Narrows FY 2012 Revenue Guidance To A Range In Line With Analysts' Estimates
Bacterin International Holdings Inc announced that it is narrowing its fiscal 2012 revenue guidance to $35 million to $37 million, within the previously stated revenue guidance range of $35 million to $40 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $36 million for fiscal 2012. Full Article
Bacterin International Holdings Inc Secures $25 Million Financing with OrbiMed
Bacterin International Holdings Inc announced the closing of a $25 million non-dilutive financing with an affiliate of OrbiMed Advisors LLC. The financing will enable Bacterin to execute its growth strategy through anticipated profitability. Under the terms of the agreement, Bacterin initially received $20 million and has the ability to draw down an additional $5 million based upon the achievement of mutually agreed upon revenue objectives prior to December 31, 2013. The Company received net proceeds of approximately $10 million after repayment of existing indebtedness as well as other transaction related fees and expenses. Net proceeds will be used by the Company for general working capital purposes. No equity securities or warrants were issued as part of the transaction. Full Article
Bacterin International Holdings Inc Comments On H2 2012 Revenue guidance; Issues Q3 2012 EBITDA Guidance Above Analysts' Estimates; Reaffirms FY 2012 Revenue Guidance
Bacterin International Holdings Inc announced that with backorder behind, inventory levels up and planned clean room expansion for third quarter, it expects continuing increased revenues in the second half of 2012 enabling to achieve stated fiscal 2012 annual revenue guidance. Gross margin of 72% was within previous guidance and operating expenses decreased from the first quarter of 2012 enabling to report positive EBITDA for the third quarter 2012, and a 54% reduction in EBTIDA loss for the first half of 2012 compared to the prior periods. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $36 million for fiscal 2012; EBITDA of $(0.99) million for the third quarter 2012. Full Article
Bacterin International Holdings Inc Lowers FY 2012 Revenue Guidance; Secures Contract
Bacterin International Holdings Inc announced that it is revising guidance from its previously stated expectation of fiscal 2012 revenues of $53-$56 million down to $35-40 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $51 million for fiscal 2012. The Company also announced that its third national GPO contract, a three-year agreement with Novation, a leading health care supply chain expert and contracting company. The agreement provides Bacterin's full biologic portfolio, including OsteoSponge, OsteoSelect DBM Putty, OsteoWrap, OsteoLock, BacFast, hMatrix, Sports Medicine Allografts, and traditional allografts to the nationwide network of hospitals and medical practices served by Novation. The group purchasing agreement became effective, after performing months of research and evaluation of the Bacterin product lines. Full Article
Peer Review Determines Bacterin International Holdings Inc's OsteoSponge Superior To Autograft And Ideal For Bone Regeneration In Dove Press Journal
Bacterin International Holdings, Inc. announced that a peer review article in Dove Press Journal has determined its OsteoSponge allograft exhibits ideal properties for bone regeneration, similar to those of autografts (graft of patient's own bone) with the distinct advantage over autografts, in that there is no risk of complications at the harvest site or donor pain postoperatively. The article describes the rationale for, and characteristics of, the OsteoSponge, summarizing the results from preclinical and human studies, and includes a discussion of the strengths and limitations of different types of bone graft for the treatment of osseous defects. The OsteoSponge allograft consists of 100% demineralized human cancellous bone, with no additional carrier materials. The OsteoSponge is compressible, allowing precise graft placement in most osseous defects; subsequent expansion completely fills the void. Full Article
Bacterin International Holdings Inc Reaffirms FY 2012 Revenue Guidance-Conference Call
Bacterin International Holdings Inc announced that for fiscal 2012, it is comfortable with the previously stated expectation of $53-$56 million revenue. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
